McGowan Institute for Regenerative Medicine

What McGowan Institute for Regenerative Medicine does

McGowan Institute for Regenerative Medicine is a joint academic research program of the University of Pittsburgh and the University of Pittsburgh Medical Center (UPMC), based in Pittsburgh, Pennsylvania, with a 30-year track record in regenerative medicine. Its mission is to develop and deliver therapies that reestablish tissue and organ function impaired by disease, trauma, or congenital abnormalities, serving patients with conditions including volumetric muscle loss, diabetic wounds, and organ failure.

The institute's technology platform centers on extracellular matrix (ECM) scaffolds — biologically derived materials that modulate immune response and recruit endogenous stem/progenitor cells — extended through Tissue Nanotransfection (a bioelectronic gene-delivery device), Matrix-Bound Nanovesicles (MBV), calcium phosphate NanoCaPs for bone regeneration, FRESH 3D bioprinting, and HemoStratum vascular surface modification. Underpinning these are more than 70 issued US patents and 400+ worldwide associated with its faculty (notably Dr. Stephen Badylak), and over 100 FDA-approved medical devices across every major body system, with more than 13 million patients treated.

As an academic institute, McGowan does not sell products directly. Its revenue mechanics are grant-funded research (DARPA, NIH, DoD, ERC), institutional support from Pitt and UPMC, philanthropy, and technology licensing to spinouts and partners (ACell/Integra, ECM Therapeutics, GenSight Biologics, Pixium Vision, Lubrizol). Clinical translation occurs via UPMC's healthcare network, DoD-funded trials (e.g., NCT04051242), and academic medical center collaborations, with federal grants functioning as the dominant funding channel.

Name

McGowan Institute for Regenerative Medicine

Legal name

McGowan Institute for Regenerative Medicine

Website

https://mirm-pitt.net

Company type

Private

Operating status

Operating

Short description

The McGowan Institute for Regenerative Medicine is a joint University of Pittsburgh and UPMC research program developing extracellular matrix scaffolds, tissue nanotransfection, and 3D bioprinting therapies to restore tissue and organ function in patients with trauma, disease, or congenital damage.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ), Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

Keywords

• Regenerative medicine research
• Tissue engineering
• Extracellular matrix technology
• Cellular therapy development
• Biologic scaffold devices

Headquarters

HQ city

Pittsburgh

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Distribution channels3 records

Marketing channels7 records

Core offering

The McGowan Institute for Regenerative Medicine develops and translates regenerative medicine technologies that restore tissue and organ function impaired by disease, trauma, or congenital abnormalities. Core offerings include Extracellular Matrix (ECM) scaffolds, Tissue Nanotransfection technology, Matrix-Bound Nanovesicles, NanoCaPs for bone regeneration, FRESH 3D bioprinting, and artificial organ/ECMO devices, which are advanced through preclinical research, clinical trials, and technology licensing to industry partners.

Product overview

The McGowan Institute for Regenerative Medicine is a national center of excellence developing and delivering regenerative therapies that restore tissue and organ function. The institute operates as a platform of interconnected research programs and clinical initiatives, unified by core technologies including Extracellular Matrix (ECM) scaffolds, Tissue Nanotransfection, and Matrix-Bound Nanovesicles. ECM Scaffolds serve as the foundational biologic platform enabling tissue repair across multiple therapeutic areas. Tissue Nanotransfection Technology extends this capability with bioelectronic gene delivery for in vivo applications. The institute's clinical portfolio includes FDA-cleared products like XenMatrix™ AB Surgical Graft alongside experimental therapies for volumetric muscle loss, diabetic wound healing, and cardiovascular applications. Specialized programs in Space Biomedicine and HemoStratum vascular technology expand the portfolio into novel domains. Research infrastructure includes core facilities (Histology Lab, Flow Cytometry Core) supporting the translational pipeline from basic science to clinical application.

Differentiator

Problem solved

Functional benefit

Brands

• McGowan Institute: Primary branding for the institute focused on regenerative medicine research and development.

Products and services

• Extracellular Matrix (ECM) Scaffolds Biologic scaffold material derived from extracellular matrix (ECM) used for tissue repair and remodeling. ECM scaffolds promote constructive and functional tissue repair by modulating the immune response and recruiting endogenous stem/progenitor cells. Licensed to medical device companies including ACell (now Integra) and ECM Therapeutics.
• Tissue Nanotransfection Technology Minimally invasive bioelectronic device using nanochannel-based electroporation to deliver genetic material directly into living tissue for therapeutic gene editing applications including wound healing, tissue regeneration, and diabetic ischemic wound healing.
• Matrix-Bound Nanovesicles (MBV) Nanoscale vesicles embedded within ECM that contain bioactive molecules including interleukin-33 (IL-33). MBVs mediate macrophage activation and are being investigated for therapeutic applications including rheumatoid arthritis treatment and tissue remodeling.
• XenMatrix AB Surgical Graft FDA 510(k) cleared xenogeneic surgical graft with antibiotic coating for soft tissue reinforcement, hernia repair, and muscle flap reinforcement. Used in DoD-funded clinical trials for volumetric muscle loss treatment.
• NanoCaPs (Nanostructured Complexes) Nanostructured calcium phosphate complexes invented by Dr. Prashant Kumta for delivering plasmid genes and growth factors to promote bone regeneration in patients with bone loss from traumatic injury, osteoporosis, and bone cancer.
• HemoStratum Vascular Biomaterial Technology Vascular biomaterial surface modification technology that alters surfaces to promote endothelial cell proliferation and blood compatibility, targeting reduction of thrombosis-related complications in vascular devices.
• Artificial Organs and ECMO Devices ECMO (Extracorporeal Membrane Oxygenation) and artificial lung technologies developed at the Medical Devices Laboratory for respiratory support.
• ECM Hydrogels and Gels

Quantifiable outcome

• 37.3% improvement in strength and 27.1% improvement in range-of-motion tasks in VML patients within 6 months of ECM implantation
• +2 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

17 partnerships are on record, tiered core and flagship.

• Ri.MED FoundationcoreStrategic or Co-development Partner · 1 January 2025Project partner in HemoStratum project led by Dr. Antonio D'Amore. European Research Council awarded Proof of Concept grant to project focused on vascular biomaterials surfaces.
• IRCCS ISMETTcoreStrategic or Co-development Partner · 1 January 2025Project partner in HemoStratum project developing vascular biomaterials technology.
• University of PalermocoreStrategic or Co-development Partner · 1 January 2025Project partner in HemoStratum project developing vascular biomaterials technology.
• Defense Advanced Research Projects Agency (DARPA)flagshipStrategic or Co-development Partner · 1 January 2020Multi-institution research team led by Dr. Stephen Badylak secured a $22 million grant from DARPA in 2020 to develop a device combining artificial intelligence, bioelectronics, and regenerative medicine to regrow muscle tissue, especially after combat injuries. This 4-year DARPA opportunity, described as a 'mini-Manhattan Project' for wound healing, involves cross-disciplinary collaboration.
• Lubrizol CorporationcoreStrategic or Co-development Partner · 1 January 2013Partnership between University of Pittsburgh and Lubrizol began in 2013 to foster future of chemistry and engineering science. Original four-year $1.4 million alliance received $1 million renewal in 2022. Yields advancements in manufacturing, sustainability, and has generated $9 million in external funding and support for nearly 30 graduate and postdoctoral students.
• Carnegie Mellon UniversitycoreStrategic or Co-development PartnerResearch partner in the DARPA-funded muscle regeneration project. McGowan Institute affiliated faculty include CMU professors. Collaborative research in 3D bioprinting through Carnegie Mellon's Regenerative Biomaterials and Therapeutics Group.
• Northwestern UniversitycoreStrategic or Co-development PartnerResearch partner in the DARPA-funded muscle regeneration project.
• Rice UniversitycoreStrategic or Co-development PartnerResearch partner in the DARPA-funded muscle regeneration project.
• University of VermontcoreStrategic or Co-development PartnerResearch partner in the DARPA-funded muscle regeneration project.
• University of WisconsincoreStrategic or Co-development PartnerResearch partner in the DARPA-funded muscle regeneration project.
• Walter Reed National Military Medical CentercoreStrategic or Co-development PartnerResearch partner in the DARPA-funded muscle regeneration project focused on combat injury treatment.
• ACell, Inc. (now part of Integra)coreOEM/ Whitelabel/ Licensing PartnerMedical device company founded by Dr. Stephen Badylak, focused on extracellular matrix products. Now part of Integra LifeSciences.
• ECM Therapeutics, Inc.coreOEM/ Whitelabel/ Licensing PartnerMedical device company founded by Dr. Stephen Badylak, actively developing products in several clinical markets including gastrointestinal, musculoskeletal, cardiovascular, and central nervous system. Has licensed multiple ECM technologies from McGowan Institute.
• Mayo ClinicflagshipStrategic or Co-development PartnerMulti-year research agreement focused on transforming transplants through advanced research initiatives including the Bioengineered Organs Initiative to create a new generation of long-term replacement organs.
• University of PittsburghflagshipStrategic or Co-development PartnerMcGowan Institute is a program of the University of Pittsburgh, providing academic infrastructure, faculty, and research capabilities.
• University of Pittsburgh Medical Center (UPMC)flagshipStrategic or Co-development PartnerMcGowan Institute is a program of UPMC, providing clinical infrastructure, patient access, and translation capabilities for regenerative medicine therapies.
• Diabetic Foot ConsortiumcoreStrategic or Co-development PartnerSix U.S. research institutions collaborating on diabetic foot research since 2020, coordinated through NIH-funded initiatives.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Wake Forest Institute for Regenerative Medicine: One of the leading academic regenerative medicine research centers in the U.S., pioneering tissue engineering and organ fabrication. Highly comparable to McGowan in mission, scale of translational activity, and focus on engineering functional human tissues and organs.
• Mayo Clinic Center for Regenerative Medicine: Flagship clinical partner of McGowan and direct peer in academic regenerative medicine. Operates the Bioengineered Organs Initiative and shares translational mission, clinical infrastructure, and patient population access through academic medical center networks.
• Harvard Wyss Institute for Biologically Inspired Engineering: Elite academic translational research institute focused on bioinspired materials, organ-on-chip technologies, and 3D bioprinting. Comparable to McGowan in translational scope, IP generation, and operating within a major university hospital ecosystem.
• Stanford Institute for Stem Cell Biology and Regenerative Medicine: Academic regenerative medicine institute pursuing cellular therapies and tissue engineering with deep patent and clinical translation activity. Comparable to McGowan in faculty caliber, funding scale, and focus on stem cell-based tissue repair.
• Cedars-Sinai Regenerative Medicine Institute: Academic medical center-based regenerative medicine institute working on cellular therapies, wound healing, and tissue engineering. Similar operating model to McGowan as a hospital-embedded translational research entity.

Broad incumbents

• Integra LifeSciences: Acquired ACell (founded by Dr. Badylak) and commercializes ECM-derived regenerative products including wound matrices and surgical grafts. Direct commercialization counterparty for McGowan ECM technology and broad medical device incumbent in the same clinical categories.
• Organogenesis: Public commercial leader in regenerative medicine, focused on wound care and surgical biologics. Directly competes with McGowan-licensed ECM products in advanced wound care and is a key benchmark for commercial translation of academic regenerative medicine IP.
• MiMedx: Commercial regenerative medicine company specializing in placental and tissue-based allografts for wound care and surgical recovery. Direct commercial competitor to ECM-derived products originating from McGowan's research.
• Mesoblast: Public cellular therapy company developing mesenchymal lineage cell therapies for inflammatory and degenerative diseases. Comparable to McGowan in regenerative medicine focus but operating at later clinical and commercial stages.

Emerging players

• ECM Therapeutics: Licensing partner founded by Dr. Stephen Badylak, actively developing ECM-derived products in gastrointestinal, musculoskeletal, cardiovascular, and CNS markets. Direct commercial spinout of McGowan ECM IP and emerging competitive threat in same technology category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@McGowanInstitute
• Xx.com/McGowanRM
• Facebookfacebook.com/McGowanInstitute

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about McGowan Institute for Regenerative Medicine